In a repeat dose study, we tested three doses of RGD4C-AAVP-TNF (5 × 109, 5 × 1010, and 5 × 1011 TU), administered on days 5, 8, 11, and 14 after tumor intracranial implantation (Fig. 1a). Here, TNF is linked to neoplasm.